We previously reported reduced DR leakage in diabetic retinopathy by treatment with ML49.3 mAb and EBP2 hFab, including dose-dependence of EBP2 hAb [15,18]. This evidence concerns the gene EBNA1BP2 and diabetic retinopathy.